No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura

摘要

Romiplostim and eltrombopag (a synthetic fusion peptibody and a nonpeptide molecule, respectively) are second-generation thrombo-poietin mimetics/agonists that are structurally dissimilar to throm-bopoietin and do not induce the formation of autoantibodies. They have been recently approved for the treatment of relapsed/ resistant immune thrombocytopenia (ITP) and both are able to improve the production of new platelets, which, in this disease, are reduced by binding of antiplatelet antibodies to BM megakaryo-cytes.4 What is still not completely clear is whether these agents are cross-resistant. We describe herein 2 FTP patients who received eltrombopag as salvage therapy after they had become resistant to romiplostim.